Drugs that contain Sugammadex Sodium

1. Bridion patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44733 MSD SUB MERCK 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Jan, 2026

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265009 MSD SUB MERCK HDP-CVD methodology for forming PMD layer
Aug, 2020

(3 years ago)

US7265099 MSD SUB MERCK Use of chemical chelators as reversal agents for drug-induced neuromuscular block
Aug, 2020

(3 years ago)

US6949527 MSD SUB MERCK 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Jan, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 25, 2024
M(M-291) Jan 22, 2024
New Chemical Entity Exclusivity(NCE) Dec 15, 2020
M(M-262) Jun 09, 2023

NCE-1 date: 16 December, 2019

Market Authorisation Date: 15 December, 2015

Treatment: Reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide; Reversal of drug-induced neuromuscular block


How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage

BRIDION family patents

Family Patents